JP6524073B2 - 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法 - Google Patents
抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法 Download PDFInfo
- Publication number
- JP6524073B2 JP6524073B2 JP2016524143A JP2016524143A JP6524073B2 JP 6524073 B2 JP6524073 B2 JP 6524073B2 JP 2016524143 A JP2016524143 A JP 2016524143A JP 2016524143 A JP2016524143 A JP 2016524143A JP 6524073 B2 JP6524073 B2 JP 6524073B2
- Authority
- JP
- Japan
- Prior art keywords
- subject
- weight gain
- polymorphisms
- antipsychotic
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892094P | 2013-10-17 | 2013-10-17 | |
| US61/892,094 | 2013-10-17 | ||
| PCT/CA2014/051000 WO2015054792A1 (en) | 2013-10-17 | 2014-10-17 | Genetic markers for antipsychotic induced weight gain and methods for use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534715A JP2016534715A (ja) | 2016-11-10 |
| JP2016534715A5 JP2016534715A5 (https=) | 2017-11-24 |
| JP6524073B2 true JP6524073B2 (ja) | 2019-06-05 |
Family
ID=52827506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524143A Expired - Fee Related JP6524073B2 (ja) | 2013-10-17 | 2014-10-17 | 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10301678B2 (https=) |
| EP (2) | EP3058106B1 (https=) |
| JP (1) | JP6524073B2 (https=) |
| KR (1) | KR102252926B1 (https=) |
| CN (1) | CN106029901A (https=) |
| AU (1) | AU2014336928B2 (https=) |
| CA (1) | CA2943951C (https=) |
| ES (1) | ES2728072T3 (https=) |
| IL (1) | IL245159B (https=) |
| PT (1) | PT3058106T (https=) |
| SG (1) | SG11201602998QA (https=) |
| WO (1) | WO2015054792A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210033619A1 (en) * | 2018-02-09 | 2021-02-04 | Metabolomic Diagnostics Limited | Methods of predicting pre term birth from preeclampsia using metabolic and protein biomarkers |
| CN110317868B (zh) * | 2019-08-09 | 2020-05-19 | 新疆医科大学第二附属医院 | 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法 |
| CN117547526A (zh) * | 2023-10-24 | 2024-02-13 | 首都医科大学附属北京朝阳医院 | γ-氨基丁酸GABA在制备防治奥氮平诱发的不良反应药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| JP4071277B2 (ja) | 1993-11-12 | 2008-04-02 | ピーエイチアールアイ・プロパティーズ・インコーポレーテッド | 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット |
| US20030104453A1 (en) | 2001-11-06 | 2003-06-05 | David Pickar | System for pharmacogenetics of adverse drug events |
| US8012718B2 (en) | 2006-03-31 | 2011-09-06 | Genomas, Inc. | Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs |
| US20070292962A1 (en) * | 2006-04-10 | 2007-12-20 | Duke University | Methods and compositions for genetic markers for autism |
| US7795033B2 (en) | 2007-03-19 | 2010-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods to predict the outcome of treatment with antidepressant medication |
| US8476012B2 (en) | 2008-04-18 | 2013-07-02 | Genomas, Inc. | Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| JP2015501652A (ja) | 2011-12-14 | 2015-01-19 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｇａｂｒ−ａ２診断 |
-
2014
- 2014-10-17 EP EP14854407.5A patent/EP3058106B1/en not_active Not-in-force
- 2014-10-17 US US15/029,955 patent/US10301678B2/en active Active
- 2014-10-17 SG SG11201602998QA patent/SG11201602998QA/en unknown
- 2014-10-17 AU AU2014336928A patent/AU2014336928B2/en not_active Ceased
- 2014-10-17 KR KR1020167012720A patent/KR102252926B1/ko not_active Expired - Fee Related
- 2014-10-17 WO PCT/CA2014/051000 patent/WO2015054792A1/en not_active Ceased
- 2014-10-17 JP JP2016524143A patent/JP6524073B2/ja not_active Expired - Fee Related
- 2014-10-17 EP EP19159011.6A patent/EP3561076A1/en not_active Withdrawn
- 2014-10-17 CN CN201480069450.4A patent/CN106029901A/zh active Pending
- 2014-10-17 ES ES14854407T patent/ES2728072T3/es active Active
- 2014-10-17 PT PT14854407T patent/PT3058106T/pt unknown
- 2014-10-17 CA CA2943951A patent/CA2943951C/en active Active
-
2016
- 2016-04-17 IL IL245159A patent/IL245159B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL245159A0 (en) | 2016-06-30 |
| CA2943951A1 (en) | 2015-04-23 |
| US20160237499A1 (en) | 2016-08-18 |
| CA2943951C (en) | 2022-05-31 |
| JP2016534715A (ja) | 2016-11-10 |
| CN106029901A (zh) | 2016-10-12 |
| IL245159B (en) | 2020-10-29 |
| EP3058106A1 (en) | 2016-08-24 |
| SG11201602998QA (en) | 2016-05-30 |
| EP3561076A1 (en) | 2019-10-30 |
| KR102252926B1 (ko) | 2021-05-20 |
| AU2014336928B2 (en) | 2020-07-16 |
| US10301678B2 (en) | 2019-05-28 |
| KR20160098188A (ko) | 2016-08-18 |
| PT3058106T (pt) | 2019-05-30 |
| ES2728072T3 (es) | 2019-10-22 |
| EP3058106B1 (en) | 2019-02-27 |
| WO2015054792A1 (en) | 2015-04-23 |
| EP3058106A4 (en) | 2017-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder | |
| Martucci et al. | N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels | |
| Anitha et al. | Genetic analyses of roundabout (ROBO) axon guidance receptors in autism | |
| Wang et al. | The—1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients | |
| Mostowska et al. | Genotype and haplotype analysis of WNT genes in non‐syndromic cleft lip with or without cleft palate | |
| US10435748B2 (en) | Genetic markers associated with suicide risk and methods of use thereof | |
| Vijayan et al. | Evidence of association of serotonin transporter gene polymorphisms with schizophrenia in a South Indian population | |
| JP2020089370A (ja) | 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法 | |
| JP6524073B2 (ja) | 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法 | |
| Ishiguro et al. | Supportive evidence for reduced expression of GNB1L in schizophrenia | |
| AU2014336928A1 (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| Kumari et al. | Potential role of GABAA receptor subunit; GABRA6, GABRB2 and GABRR2 gene polymorphisms in epilepsy susceptibility and pharmacotherapy in North Indian population | |
| Liu et al. | The YWHAE gene confers risk to major depressive disorder in the male group of Chinese Han population | |
| Jongjaroenprasert et al. | Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population | |
| Tzang et al. | Association study of p11 gene with major depressive disorder, suicidal behaviors and treatment response | |
| CA2664366C (en) | Slc1a1 antipsychotic drug response markers | |
| CN1973051A (zh) | 用于预测对氯氮平治疗的应答性的生物标记 | |
| HK1224705B (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| HK1224705A1 (en) | Genetic markers for antipsychotic induced weight gain and methods for use thereof | |
| Zai et al. | Weak association of the platelet-derived growth factor beta (PDGFB) and PDGF receptor beta (PDGFRB) genes with schizophrenia and schizoaffective disorder | |
| US20070048767A1 (en) | Marker for a Psychosis or a Mood Disorder | |
| KR20070022710A (ko) | 클로자핀 치료에 대한 반응성을 예측하기 위한 바이오마커 | |
| Barr et al. | XIII World Congress on Psychiatric Genetics 2005 Sponsored by | |
| CA2517218A1 (en) | Marker for psychosis or mood disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171016 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171016 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180822 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190402 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190426 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6524073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |